STOCK TITAN

Teva Pharmaceutical Industries (TEVA) Stock News

TEVA NYSE

Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.

As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.

Rhea-AI Summary

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced that CEO Richard Francis and other executives will present at three healthcare investor conferences.

The Evercore presentation is set for November 30, 2026, at 1:45 p.m. ET. On December 1, 2026, Teva will present at Piper Sandler at 8:30 a.m. ET and at Citi at 9:00 a.m. ET. A live webcast will be available on Teva’s investor relations website, with a replay within 24 hours of the live discussion ending.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Teva Pharmaceutical Industries (TEVA) announced that Eric Hughes will leave his roles as executive vice president of global R&D and chief medical officer. Hughes accepted an offer outside Teva and will stay for the coming months to help with the transition. David Gardiner takes over as R&D transition lead immediately, reporting to CEO Richard Francis until a permanent successor is named. Teva is starting the search immediately.

Teva said its Pivot to Growth strategy, R&D priorities and expectations remain unchanged, including its ambition to generate $6–7 billion in innovative medicines revenue by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.74%
Tags
management
-
Rhea-AI Summary

Teva (TEVA) received FDA approval for IGALMI as an at-home treatment for acute agitation in adults with specified psychiatric disorders. The approval covers schizophrenia, schizoaffective disorder, and bipolar I or II disorder, extending use beyond healthcare-supervised treatment.

The Phase 3 SERENITY At-Home trial met its primary safety and tolerability endpoint. Across 1,160 agitation episodes treated in 102 patients, tolerability remained consistent with repeat dosing over 12 weeks, with no discontinuations due to tolerability. Common adverse events included sleepiness, dry mouth, dizziness and mouth numbness or tingling. Serious risks include low blood pressure and slow heart rate.

Teva acquired IGALMI in late October 2026 and plans to announce at-home commercialization plans later. The supplemental approval application was submitted on January 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
Rhea-AI Summary

Teva Pharmaceutical Industries (TEVA) outlined its growth plans at R&D Day, targeting $6–7 billion in innovative medicines revenue by 2030. Innovative medicines revenue has more than doubled since the 2023 launch of Pivot to Growth and now exceeds 20% of total revenue. Teva targets mid-single-digit total revenue growth from 2026 to 2030 and more than $3.5 billion in free cash flow by 2030.

The company sees potential for one innovative medicine launch annually through 2030 and more than $10 billion in combined late-stage pipeline peak sales, subject to regulatory approvals. Those sales estimates are non-risk-adjusted and indicative. An anti-IL-15 Phase 2a celiac disease study met its primary endpoint; Teva expects Phase 2b to begin in the second half of 2027. Ecopipam received FDA priority review. Teva also targets innovative gross margins above 75% and net debt to adjusted EBITDA, a measure of earnings, of 2.0x by the end of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Summary

Medincell (MEDCL) reported that its partner Teva generated $85M in third-quarter 2026 U.S. net sales of UZEDY, its first commercial product. Sales rose 96% year-on-year, bringing nine-month U.S. net sales to $225M, above the $191M reported for full-year 2025. Teva raised its 2026 UZEDY revenue outlook to $290-$310M from $270-$290M.

Medincell receives mid- to high-single-digit royalties on UZEDY net sales and is eligible for up to $105M in commercial milestone payments, subject to annual sales thresholds. Prescriptions, measured in months of therapy, increased 62% year-on-year. The U.S. launch of WELTRUZA, a once-monthly olanzapine long-acting injection, is underway following FDA approval in October 2026. Both products use Medincell’s technology under a worldwide licensing agreement with Teva, with the same economic terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
-
Rhea-AI Summary

Teva (TEVA) raised its 2026 revenue outlook for three innovative brands as their combined third-quarter revenues grew 33% in local currency. AUSTEDO, AJOVY and UZEDY generated approximately $1.1 billion. Their revised annual revenue ranges are $2.55–$2.65 billion, $930–$960 million and $290–$310 million, respectively.

Third-quarter revenue fell 2% to $4.4 billion, while global generics revenue declined 16% in local currency. GAAP gross margin rose to 55.5% from 51.4%, but diluted EPS fell 47% to $0.20. Free cash flow declined 4% to $495 million. Full-year revenue guidance is $16.7–$17.0 billion.

Teva received October FDA approval for WELTRUZA and launched it in the U.S., acquired BXCL-501 and expanded its Samsung Bioepis collaboration. It discontinued the emrusolmin study after an interim futility analysis. Teva also returned to investment-grade credit ratings and refinanced approximately $4.9 billion of debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
Rhea-AI Summary

Teva (TEVA) signed an agreement with Samsung Bioepis for U.S. commercialization rights to two FDA-approved biosimilars for inflammatory and autoimmune conditions. Biosimilars are biological medicines referencing existing biologic treatments. The products are ETICOVO (etanercept-ykro), referencing Enbrel, and infliximab-abda, referencing Remicade.

ETICOVO rights transfer at closing; infliximab-abda rights transfer in Q3 2027. The transaction is anticipated to close by the end of 2026, subject to necessary regulatory approvals and customary closing conditions. ETICOVO is not currently available in the U.S.; its commercialization timing will be announced later. Samsung Bioepis retains manufacturing and regulatory oversight. Subject to certain conditions, Teva will make an upfront payment over the next 3 years, with possible additional launch and sales milestone payments. The companies will share commercialization profits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
-
Rhea-AI Summary

Teva (TEVA) will discontinue its Phase 2 TOPAS-MSA study of emrusolmin in adults with multiple system atrophy following an interim futility analysis. The prespecified analysis met the predefined stopping criterion, indicating a low probability of meeting the primary efficacy endpoint if the study continued. An independent data monitoring committee recommended discontinuation. This was a predictive interim assessment, not the final efficacy analysis; no safety concerns were identified.

Teva plans a comprehensive analysis of TOPAS-MSA and available open-label extension data, with findings to be shared after that analysis. The decision concerns TOPAS-MSA and is not a final decision on the broader emrusolmin program, which is being developed with MODAG. Teva will work with investigators to follow study protocols during discontinuation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.30%
Tags
-
Rhea-AI Summary

Teva (TEVA) has completed its acquisition of BioXcel Therapeutics’ neuroscience assets, including worldwide rights to BXCL501, for $57.5 million upfront. The asset purchase also carries up to $67.5 million in contingent payments, linked to regulatory approval timing, including potential delays, and specified sales milestones.

BXCL501 is an investigational, orally dissolving dexmedetomidine film under FDA review for at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults. Teva said approval would make it the first FDA-approved treatment patients could use at home for this condition. The acquired assets also include worldwide rights to IGALMI, an FDA-approved dexmedetomidine film for treatment in a hospital setting. The court-supervised asset sale closed after U.S. Bankruptcy Court approval and satisfaction of other closing conditions; Teva did not acquire BioXcel Therapeutics itself.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.10%
Tags
Rhea-AI Summary

Teva (TEVA) and Sanofi reported that investigational duvakitug maintained efficacy through 44 weeks of maintenance treatment in a phase 2b extension.

The study enrolled 130 responders from a 14-week induction study, including 72 with ulcerative colitis (UC) and 58 with Crohn’s disease (CD). Patients received 450 mg or 900 mg every four weeks. At Week 44, UC clinical remission was 47% and 58%, respectively; CD endoscopic response, measuring improvement in intestinal inflammation, was 41% and 55%. Results were descriptive. No new safety concerns were identified, and most adverse events were mild or moderate.

Induction-study biomarker analyses showed reductions in inflammation markers and, in CD, tissue-remodeling markers. Duvakitug is in phase 3 studies for UC and CD. The partners have initiated a phase 2 hidradenitis suppurativa study and plan a phase 2 fibrostenotic CD study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags

FAQ

What is the current stock price of Teva Pharmaceutical Industries (TEVA)?

Teva Pharmaceutical Industries (TEVA) last closed at $39.23.

What is the market cap of Teva Pharmaceutical Industries (TEVA)?

The market cap of Teva Pharmaceutical Industries (TEVA) is approximately $45.8B.